Skip to main content

Advertisement

Table 1 Patients’ demographic and baseline fertility characteristics overall and by treatment group (primary efficacy analysis population)

From: Phase IV, open-label, randomized study of low-dose recombinant human follicle-stimulating hormone protocols for ovulation induction

Variable CLD group LD group Total
(n = 122) (n = 125) (N = 247)
Age, years a n 122 124 246
  Mean (SD) 27.5 (4.42) 27.9 (4.33) 27.7 (4.37)
BMI, kg/m 2 a n 119 124 243
Mean (SD) 26.4 (2.95) 26.0 (3.14) 26.2 (3.05)
Race b n 122 124 246
Arab n (%) 68 (55.7) 69 (55.6) 137 (55.7)
Asian n (%) 19 (15.6) 16 (12.9) 35 (14.2)
Black n (%) 1 (0.8) 4 (3.2) 5 (2.0)
Caucasian n (%) 33 (27.1) 34 (27.4) 67 (27.2)
Other n (%) 1 (0.8) 1 (0.8) 2 (0.8)
Infertility type b n 122 125 247
Primary n (%) 92 (75.4) 96 (76.8) 188 (76.1)
Secondary n (%) 30 (24.6) 29 (23.2) 59 (23.9)
Duration of infertility, years a n 122 125 247
  Mean (SD) 3.8 (2.57) 4.2 (2.48) 4.0 (2.53)
Cause of infertility b n 123c 127c 250c
Ovulatory dysfunction n (%) 120 (97.6) 121 (95.3) 241 (96.4)
Tubal factor n (%) 0 (0.0) 1 (0.8) 1 (0.4)
Other n (%) 3 (2.4) 5 (3.9) 8 (3.2)
Previous infertility treatment b n 122 125 247
Yes n (%) 90 (73.8) 103 (82.4) 193 (78.1)
No n (%) 32 (26.2) 22 (17.6) 54 (21.9)
Previous pregnancies b n 122 125 247
None n (%) 92 (75.4) 94 (75.2) 186 (75.3)
At least one n (%) 30 (24.6) 31 (24.8) 61 (24.7)
  1. aNot significant; t-test.
  2. bNot significant; Chi-square test.
  3. cMultiple causes of infertility in three patients (CLD group, n = 1; LD group, n = 2).
  4. BMI = body mass index; CLD = chronic low-dose; LD = low-dose; SD = standard deviation.